All In Biotech

Drug Trial Radar · NCT00847626

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension

Last checked: Nov 19, 2026Latest source record: Feb 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,711 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,711

Actual

Start

Jan 2009

Primary completion

May 2010

Study completion Jul 2010

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Feb 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.

Conditions

  • Hypertension

Interventions

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomil and chlorthalidoneDrug

    Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

  • ChlorthalidoneDrug

    Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks

  • ChlorthalidoneDrug

    Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomilDrug

    Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomilDrug

    Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

  • Azilsartan medoxomilDrug

    Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)Time frame: Baseline and Week 8.
  2. Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pairwise Analysis)Time frame: Baseline and Week 8.

Locations

99 sites in 5 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Columbiana, Alabama

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Chandler, Arizona

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Tucson, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Buena Park, California

  • Site not named

    Carmichael, California

  • Site not named

    Costa Mesa, California

  • Site not named

    Irvine, California

  • Site not named

    Palm Springs, California

  • Site not named

    Riverside, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    Vista, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Middletown, Delaware

  • Site not named

    Bradenton, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Hallandale, Florida

  • Site not named

    Hialeah, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Longwood, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Ocala, Florida

  • Site not named

    Ormond Beach, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Buffalo Grove, Illinois

  • Site not named

    Libertyville, Illinois

  • Site not named

    Melrose Park, Illinois

  • Site not named

    Fishers, Indiana

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Erlanger, Kentucky

  • Site not named

    Madisonville, Kentucky

  • Site not named

    Paducah, Kentucky

  • Site not named

    Rockville, Maryland

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.